Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | GLS | O94925 | 2/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249437 | 0.91 | CYP17A1 (0.68) | DRD2GLSCYP17A1NAMPTNPC1 | |
| SCHEMBL1854209 | 0.88 | ATM (0.56) | DRD2GLSCYP17A1NAMPTNPC1 | |
| SCHEMBL7156537 | 0.87 | MGLL (0.52) | DRD2GLSNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1000732 | 0.86 | NR1H4 (0.58) | DRD2GLSCYP17A1NAMPTPTGDR2 | |
| SCHEMBL13234660 | 0.86 | PPARA (0.59) | DRD2NPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL12677009 | 0.86 | CYP17A1 (0.58) | DRD2GLSCYP17A1NAMPTNPC1 | |
| SCHEMBL27493682 | 0.86 | CYP17A1 (0.58) | DRD2GLSCYP17A1NAMPTNPC1 | |
| SCHEMBL16246084 | 0.86 | CYP17A1 (0.58) | DRD2GLSCYP17A1NAMPTNPC1 | |
| SCHEMBL2244813 | 0.86 | CYP17A1 (0.58) | DRD2GLSCYP17A1NAMPTPTGDR2 | |
| SCHEMBL7043026 | 0.85 | POLB (0.62) | CYP17A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6251919-B1 | ADMINISTERING ANILINE DERIVATIVE FOR THERAPY OF PAIN | WARNER-LAMBERT | 2001-06-26 | — | — | US | disclosed |
| WO-1999043658-A1 | HETEROCYCLIC SUBSTITUTED ANILINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | DRD2 3003/4885GLS 2121/4885CYP17A1 2063/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | DRD2 3003/4885GLS 2121/4885CYP17A1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.